ZFGN Zafgen Inc

Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen, will present at the 2017 Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 26, 2017 at 1:00 p.m. ET.

A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website (www.zafgen.com) for 90 days following the conclusion of the live event.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. The Company has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity, and in patients affected by type 2 diabetes. Zafgen’s lead product candidate is ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor that was advanced into development due to its unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. The Company recently completed its first Phase 1 clinical trial of ZGN-1061, and is in Phase 2 clinical testing in patients with type 2 diabetes who are overweight or obese. Zafgen holds exclusive worldwide rights for the development and commercialization of ZGN-1061. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.

Media/Investor Relations Contact:

Zafgen, Inc.Patricia AllenChief Financial Officer617-648-9792

Argot PartnersInvestor RelationsLaura Perry 212-600-1902laura@argotpartners.com

Spectrum ScienceMedia RelationsMichelle Strier202-587-2582mstrier@spectrumscience.com